KR102218320B1 - Method of preparing(3r,5r)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-((4-hydroxymethylphenylamino)carbonyl)-pyrrol-1-yl)-3,5-dihydroxy-heptanoic acid hemi calcium salt, and method of preparing intermediates used therein - Google Patents

Method of preparing(3r,5r)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-((4-hydroxymethylphenylamino)carbonyl)-pyrrol-1-yl)-3,5-dihydroxy-heptanoic acid hemi calcium salt, and method of preparing intermediates used therein Download PDF

Info

Publication number
KR102218320B1
KR102218320B1 KR1020190084527A KR20190084527A KR102218320B1 KR 102218320 B1 KR102218320 B1 KR 102218320B1 KR 1020190084527 A KR1020190084527 A KR 1020190084527A KR 20190084527 A KR20190084527 A KR 20190084527A KR 102218320 B1 KR102218320 B1 KR 102218320B1
Authority
KR
South Korea
Prior art keywords
formula
compound
preparing
fluorophenyl
phenyl
Prior art date
Application number
KR1020190084527A
Other languages
Korean (ko)
Other versions
KR20210008263A (en
Inventor
박은정
정서희
박상욱
이원일
손세일
유진호
Original Assignee
대원제약주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 대원제약주식회사 filed Critical 대원제약주식회사
Priority to KR1020190084527A priority Critical patent/KR102218320B1/en
Priority to CN202080049765.8A priority patent/CN114096523A/en
Priority to PCT/KR2020/009130 priority patent/WO2021010681A2/en
Publication of KR20210008263A publication Critical patent/KR20210008263A/en
Application granted granted Critical
Publication of KR102218320B1 publication Critical patent/KR102218320B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/337Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

본 발명은(3R,5R)-7-(2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-((4-히드록시 메틸 페닐 아미노)카보닐)-피롤-1-일)-3,5-디히드록시 헵탄산 헤미칼슘염의 제조방법을 제공한다. 본 발명의 제조방법은 (3R,5R)-7-(2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-((4-히드록시메틸페닐아미노)카보닐)-피롤-1-일)-3,5-디히드록시 헵탄산 헤미칼슘염의 주요 구조부들 각각을 개별적으로 합성한 후 커플링 하는 수렴합성 방식으로 수행된다. 이에 따라, 유연물질을 용이하게 제어하고 제조시간을 단축시킬 수 있어 화합물의 생산성을 향상시킬 수 있고, 최종 화합물의 수율 또한 높일 수 있다.The present invention is (3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-((4-hydroxy methyl phenyl amino)carbonyl)-pyrrole-1 -Yl)-3,5-dihydroxyheptanoic acid hemicalcium salt production method is provided. The production method of the present invention is (3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-((4-hydroxymethylphenylamino)carbonyl)-pyrrole -1-yl)-3,5-dihydroxyheptanoate hemicalcium salt is synthesized individually and then coupled to each of the major structural parts. Accordingly, the related material can be easily controlled and the manufacturing time can be shortened, thereby improving the productivity of the compound, and also increasing the yield of the final compound.

Description

(3R,5R)-7-(2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-((4-히드록시메틸페닐아미노)카보닐)-피롤-1-일)-3,5-디히드록시 헵탄산 헤미칼슘염의 제조방법, 및 이에 사용되는 중간체의 제조방법{METHOD OF PREPARING(3R,5R)-7-(2-(4-FLUOROPHENYL)-5-ISOPROPYL-3-PHENYL-4-((4-HYDROXYMETHYLPHENYLAMINO)CARBONYL)-PYRROL-1-YL)-3,5-DIHYDROXY-HEPTANOIC ACID HEMI CALCIUM SALT, AND METHOD OF PREPARING INTERMEDIATES USED THEREIN}(3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-((4-hydroxymethylphenylamino)carbonyl)-pyrrol-1-yl)- Method for preparing 3,5-dihydroxy hemicalcium salt hemicalcium salt, and method for preparing intermediates used therein {METHOD OF PREPARING(3R,5R)-7-(2-(4-FLUOROPHENYL)-5-ISOPROPYL-3- PHENYL-4-((4-HYDROXYMETHYLPHENYLAMINO)CARBONYL)-PYRROL-1-YL)-3,5-DIHYDROXY-HEPTANOIC ACID HEMI CALCIUM SALT, AND METHOD OF PREPARING INTERMEDIATES USED THEREIN}

본 발명은 (3R,5R)-7-(2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-((4-히드록시메틸페닐아미노)카보닐)-피롤-1-일)-3,5-디히드록시 헵탄산 헤미칼슘염의 제조방법 및 이에 사용되는 중간체의 제조방법에 관한 것이다.The present invention is (3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-((4-hydroxymethylphenylamino)carbonyl)-pyrrol-1- It relates to a method for preparing the hemicalcium salt of day)-3,5-dihydroxyheptanoic acid and a method for preparing an intermediate used therein.

(3R,5R)-7-(2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-((4-히드록시메틸페닐아미노)카보닐)-피롤-1-일)-3,5-디히드록시 헵탄산 헤미칼슘염은 3-히드록시-3-메틸글루타릴-코엔자임 A 환원효소의 저해제로 작용하여, 콜레스테롤의 세포 내에서의 합성을 저해하여 지질 강하제 또는 콜레스테롤 강하제로서 유용하다.(3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-((4-hydroxymethylphenylamino)carbonyl)-pyrrol-1-yl)- Hemicalcium salt of 3,5-dihydroxy heptanoate acts as an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, inhibiting the synthesis of cholesterol in cells, and thus a lipid-lowering or cholesterol-lowering agent. It is useful as

대한민국 등록특허 제10-1329112호에는 (3R,5R)-7-[2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-[(4-히드록시메틸페닐아미노)카보닐]-피롤-1-일]-3,5-디히드록시-헵탄산 헤미칼슘염을 제조하는 방법이 하기 반응식과 같이 기재되어 있다.Korean Patent Registration No. 10-1329112 discloses (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxymethylphenylamino)carbonyl ]-Pyrrole-1-yl]-3,5-dihydroxy-heptanoic acid hemicalcium salt is described in the following scheme.

Figure 112019071648864-pat00001
Figure 112019071648864-pat00001

(상기 제조방법의 반응식에서 R은 알킬, 아릴 또는 알킬아릴임)(In the reaction formula of the above preparation method, R is alkyl, aryl or alkylaryl)

그러나 상기 제조방법에 따르면, 사용되는 벤즈알데히드로 인해 유연물질이 발생하고, 이로 인해 생성된 유연물질의 제거가 어렵다. 또한, 치환체를 하나씩 순차적으로 합성하여 중간단계에 문제가 발생할 시 처음부터 다시 시작해야 하여 공정시간이 많이 소요된다. 따라서, 종래의 제조방법은 대량합성에 적합하지 않은 문제점이 있었다.However, according to the above manufacturing method, related substances are generated due to the benzaldehyde used, and thus it is difficult to remove the generated related substances. In addition, when a problem occurs in an intermediate step by sequentially synthesizing the substituents one by one, it takes a lot of time to start again from the beginning. Therefore, the conventional manufacturing method has a problem that is not suitable for mass synthesis.

이에, 본 발명자들은 상기 종래와 같은 순차합성 방법이 아니라, 화합물의 주요 구조부들을 각각 별개로 합성한 후 커플링시키는 수렴합성 방법에 의해 효과적으로 (3R,5R)-7-[2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-[(4-히드록시메틸페닐아미노)카보닐]-피롤-1-일]-3,5-디히드록시 헵탄산 헤미칼슘염을 합성할 수 있고, 반응 중간체를 고체로 합성할 수 있을 뿐 아니라 주요 유연물질을 쉽게 제어할 수 있는 방법을 고안하여 본 발명을 완성하였다.Accordingly, the present inventors effectively synthesize (3R,5R)-7-[2-(4-) by a convergent synthesis method in which the main structural parts of the compound are separately synthesized and then coupled, rather than the conventional sequential synthesis method. Synthesis of fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxymethylphenylamino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy heptanoic acid hemicalcium salt The present invention has been completed by devising a method that can easily control the main related substances as well as synthesize the reaction intermediate as a solid.

대한민국 등록특허 제10-1329112호Korean Patent Registration No. 10-1329112

본 발명의 일 목적은 종래의 순차합성 방법의 단점들을 효과적으로 해결할 수 있는 새로운 (3R,5R)-7-[2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-[(4-히드록시메틸페닐아미노)카보닐]-피롤-1-일]-3,5-디히드록시 헵탄산 헤미칼슘염의 제조방법을 제공하는 것이다.One object of the present invention is a novel (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[ which can effectively solve the shortcomings of the conventional sequential synthesis method. It is to provide a method for producing (4-hydroxymethylphenylamino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy heptanoic acid hemicalcium salt.

본 발명의 다른 목적은 (3R,5R)-7-[2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-[(4-히드록시메틸페닐아미노)카보닐]-피롤-1-일]-3,5-디히드록시 헵탄산 헤미칼슘염의 제조에 사용되는 중간체의 제조방법을 제공하는 것이다.Another object of the present invention is (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxymethylphenylamino)carbonyl]-pyrrole It is to provide a method for preparing an intermediate used in the preparation of -1-yl]-3,5-dihydroxy hemicalcium hemicalcium salt.

상기 과제를 해결하기 위하여, 본 발명의 (3R,5R)-7-[2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-[(4-히드록시메틸페닐아미노)카보닐]-피롤-1-일]-3,5-디히드록시 헵탄산 헤미칼슘염의 제조방법은,In order to solve the above problems, (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxymethylphenylamino)carbo of the present invention Neil]-pyrrol-1-yl]-3,5-dihydroxy heptanoic acid hemicalcium salt production method,

(S1) 하기 화학식 A의 화합물과 하기 화학식 B의 화합물을 반응시켜, 하기 화학식 C의 화합물을 제조하는 단계;(S1) preparing a compound of the following formula C by reacting a compound of the following formula A with a compound of the following formula B;

(S2) 화학식 C의 화합물과 하기 화학식 D의 화합물을 반응시켜, 하기 화학식 E의 화합물을 제조하는 단계;(S2) reacting a compound of formula C with a compound of formula D to prepare a compound of formula E;

(S3) 화학식 E의 화합물로부터 하기 화학식 F의 화합물을 제조하는 단계;(S3) preparing a compound of the following formula F from the compound of formula E;

(S4) 화학식 F의 화합물로부터 하기 화학식 G의 화합물을 제조하는 단계;(S4) preparing a compound of formula G from the compound of formula F;

(S5) 화학식 G의 화합물로부터 하기 화학식 H의 화합물을 제조하는 단계; 및(S5) preparing a compound of formula H from the compound of formula G; And

(S6) 화학식 H의 화합물로부터 하기 화학식 1의 화합물을 제조하는 단계를 포함한다.(S6) preparing a compound of Formula 1 below from the compound of Formula H.

[화학식 A][Formula A]

Figure 112019071648864-pat00002
Figure 112019071648864-pat00002

[화학식 B][Formula B]

Figure 112019071648864-pat00003
Figure 112019071648864-pat00003

[화학식 C][Formula C]

Figure 112019071648864-pat00004
Figure 112019071648864-pat00004

[화학식 D][Formula D]

Figure 112019071648864-pat00005
Figure 112019071648864-pat00005

[화학식 E][Formula E]

Figure 112019071648864-pat00006
Figure 112019071648864-pat00006

[화학식 F][Formula F]

Figure 112019071648864-pat00007
Figure 112019071648864-pat00007

[화학식 G][Formula G]

Figure 112019071648864-pat00008
Figure 112019071648864-pat00008

[화학식 H][Formula H]

Figure 112019071648864-pat00009
Figure 112019071648864-pat00009

[화학식 1][Formula 1]

Figure 112019071648864-pat00010
Figure 112019071648864-pat00010

상기 화학식에서, R1 및 R2는 각각 독립적으로 C1-C6알킬을 나타내고,In the above formula, R 1 and R 2 each independently represent C 1 -C 6 alkyl,

X는 이탈기(leaving group)를 나타낸다.X represents a leaving group.

이탈기는 Cl, Br 또는 I와 같은 할라이드, 토실레이트(OTs), 트리플레이트(OTf) 또는 아세테이트(OAc)일 수 있다.The leaving group may be a halide such as Cl, Br or I, tosylate (OTs), triflate (OTf) or acetate (OAc).

상기 단계 (S1)은 활성 메틸렌 화합물을 알킬화시키는 단계로서, 염기 조건 또는 중성 조건에서 수행될 수 있다. 이때, 염기 조건을 위해 이용되는 염기의 예로서는, 탄산칼륨, 탄산리튬, 탄산나트륨, 탄산세슘, 수산화리튬, 수산화나트륨, 수산화칼륨, 1,8-디아자비사이클로(5.4.0)언덱-7-엔(DBU), N,N-디이소프로필에틸아민(DIPEA), 트리에탄올아민(TEA), 피리딘, 수소화나트륨 또는 포타슘 ter-부톡사이드(K[OC(CH3)3]) 등을 들 수 있고 이들은 각각 단독으로 또는 2 이상을 혼합하여 이용할 수 있다.The step (S1) is a step of alkylating the active methylene compound, and may be performed under basic conditions or neutral conditions. At this time, examples of the base used for the base condition include potassium carbonate, lithium carbonate, sodium carbonate, cesium carbonate, lithium hydroxide, sodium hydroxide, potassium hydroxide, 1,8-diazabicyclo (5.4.0) undec-7-ene ( DBU), N,N-diisopropylethylamine (DIPEA), triethanolamine (TEA), pyridine, sodium hydride or potassium ter-butoxide (K[OC(CH 3 ) 3 ]), and the like, respectively. It can be used alone or in combination of two or more.

또한, 상기 단계 (S1)은 활성 메틸렌 화합물의 알킬화 반응에 사용될 수 있는 용매 하에서 진행될 수 있으며, 상기 용매의 예로서는, 톨루엔, 자일렌, 벤젠, 메틸렌클로라이드, 부탄올, 테트라하이드로퓨란, 에틸아세테이트, 프로판올, 사이클로헥사논, 디에틸에테르, 디옥산, 에탄올, 메탄올, 피리딘, 아세톤, 아세토니트릴, n,n-디메틸포름아미드, 디메틸술폭사이드 또는 이들의 수용액 등을 들 수 있고 이들은 각각 단독으로 또는 2 이상을 혼합하여 이용할 수 있다.In addition, the step (S1) may be carried out under a solvent that can be used in the alkylation reaction of the active methylene compound, and examples of the solvent include toluene, xylene, benzene, methylene chloride, butanol, tetrahydrofuran, ethyl acetate, propanol, Cyclohexanone, diethyl ether, dioxane, ethanol, methanol, pyridine, acetone, acetonitrile, n,n-dimethylformamide, dimethyl sulfoxide, or aqueous solutions thereof, and the like, and these may be used alone or in combination of two or more. It can be mixed and used.

상기 단계 (S2)는 화학식 C의 화합물과 화학식 D의 화합물을 커플링시켜 피롤 고리를 형성하는 단계로서, 피롤 고리화 반응에 사용될 수 있는 용매, 예를 들어, 메탄올, 에테르, 에틸아세테이트, 테트라하이드로퓨란, 톨루엔, 헵탄, 사이클로헥산 또는 헥산 등을 이용할 수 있고 이들은 각각 단독으로 또는 2 이상을 혼합하여 이용할 수 있다. 이때, 피롤 고리화 반응은 산 조건에서 진행될 수 있고, 피발산(pivalic acid)이나 톨루엔-4-술폰산 등을 이용할 수 있다.The step (S2) is a step of forming a pyrrole ring by coupling the compound of formula C and the compound of formula D, and a solvent that can be used in the pyrrole cyclization reaction, for example, methanol, ether, ethyl acetate, tetrahydro Furan, toluene, heptane, cyclohexane, or hexane may be used, and these may be used alone or in combination of two or more. At this time, the pyrrole cyclization reaction may be performed under acid conditions, and pivalic acid or toluene-4-sulfonic acid may be used.

상기 단계 (S3)은 화학식 E의 화합물에서 알킬기를 제거하는 단계로서, 산 조건에서 수행될 수 있다. 이때, 산 조건은 염산, 브롬산, 요오드산, 황산, 아세트산 또는 트리플루오로아세트산 등을 이용할 수 있고, 이들은 각각 단독으로 또는 2 이상이 혼합되어 이용될 수 있다.The step (S3) is a step of removing an alkyl group from the compound of Formula E, and may be performed under acid conditions. At this time, the acid conditions may be hydrochloric acid, bromic acid, iodic acid, sulfuric acid, acetic acid or trifluoroacetic acid, and these may be used alone or in combination of two or more.

상기 단계 (S4)는 화학식 F 내의 카르복실기를 선택적으로 환원시키는 단계로서, 환원제로서 붕소-디메틸설파이드(DMS) 착체 또는 붕소-테트라히드로푸란 착체의 존재 하에서 수행될 수 있고, 용매로서는 탄화수소 용매(예컨대, 헥산, n-헵탄 또는 톨루엔) 또는 에테르 용매(예컨대, 테트라히드로푸란, 디옥산 또는 디에틸 에테르) 등을 이용할 수 있으며 이들은 각각 단독으로 또는 2 이상이 혼합되어 이용될 수 있다.The step (S4) is a step of selectively reducing the carboxyl group in Formula F, and may be performed in the presence of a boron-dimethylsulfide (DMS) complex or a boron-tetrahydrofuran complex as a reducing agent, and as a solvent, a hydrocarbon solvent (e.g., Hexane, n-heptane or toluene) or an ether solvent (eg, tetrahydrofuran, dioxane or diethyl ether) may be used, and these may be used alone or in combination of two or more.

상기 단계 (S5)는 화학식 G의 화합물에서 산에 의한 케탈기의 고리 열림(cleavage)을 일으키는 단계로서, 극성 용매(예컨대, 메탄올, 에탄올 또는 이소프로필 알콜), 에테르 용매(예컨대, 테트라히드로푸란, 디옥산 또는 디에틸 에테르) 등을 이용할 수 있고 이들은 각각 단독으로 또는 2 이상이 혼합되어 이용될 수 있다.The step (S5) is a step of causing the cleavage of the ketal group by an acid in the compound of formula G, a polar solvent (eg, methanol, ethanol or isopropyl alcohol), an ether solvent (eg, tetrahydrofuran, Dioxane or diethyl ether) and the like may be used, and these may be used alone or in combination of two or more.

상기 단계 (S6)은 화학식 H의 화합물을 염기 조건 하에서 가수분해시킨 후, 이에 칼슘 이온 공급원을 가하여 최종 생성물인 화학식 1로 나타내는 (3R,5R)-7-[2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-[(4-히드록시메틸페닐아미노)카보닐]-피롤-1-일]-3,5-디히드록시 헵탄산 헤미칼슘염을 제조한다. 이때 가수분해 반응 및 염의 제조 반응은 메탄올, 테트라하이드로퓨란 또는 물 등의 용매 하에서 진행될 수 있고 이들은 각각 단독으로 또는 2 이상이 혼합되어 이용될 수 있다.In the step (S6), after hydrolyzing the compound of formula H under basic conditions, a calcium ion source is added thereto, and the final product is (3R,5R)-7-[2-(4-fluorophenyl) -5-isopropyl-3-phenyl-4-[(4-hydroxymethylphenylamino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy heptanoic acid hemicalcium salt is prepared. At this time, the hydrolysis reaction and the salt preparation reaction may be performed in a solvent such as methanol, tetrahydrofuran, or water, and these may be used alone or in combination of two or more.

상기 단계 (S6)에서 이용하는 칼슘 이온 공급원의 예로서는, 칼슘아세테이트, 칼슘 클로라이드, 칼슘 카보네이트, 트리칼슘 포스페이트, 칼슘 시트레이트, 칼슘 시트레이트말레이트, 칼슘 락테이트, 칼슘 글루코네이트, 칼슘 하이드록사이드, 칼슘 옥살레이트, 칼슘 플루오라이드, 칼슘 설페이트 또는 이들 수용액 등을 들 수 있다. 이들은 각각 단독으로 또는 2 이상이 혼합되어 이용될 수 있다.Examples of the calcium ion source used in the step (S6) include calcium acetate, calcium chloride, calcium carbonate, tricalcium phosphate, calcium citrate, calcium citrate maleate, calcium lactate, calcium gluconate, calcium hydroxide, calcium Oxalate, calcium fluoride, calcium sulfate, or aqueous solutions thereof. These may be used alone or in combination of two or more.

본 발명의 단계 (S1) 내지 단계 (S6)을 포함하는 화학식 1의 화합물의 제조방법은 하기 반응식 1로 나타낼 수 있다.The method for preparing the compound of Formula 1 including steps (S1) to (S6) of the present invention can be represented by the following Scheme 1.

[반응식 1] [Scheme 1]

Figure 112019071648864-pat00011
Figure 112019071648864-pat00011

화학식 C의 화합물은, 본 발명의 (3R,5R)-7-[2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-[(4-히드록시메틸페닐아미노)카보닐]-피롤-1-일]-3,5-디히드록시 헵탄산 헤미칼슘염의 제조에 이용되는 중간체로 이용되고, 화학식 A의 화합물과 화학식 B의 화합물을 반응시켜 제조한다.The compound of formula C is (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxymethylphenylamino)carbonyl of the present invention. ]-Pyrrole-1-yl]-3,5-dihydroxyheptanoic acid hemicalcium salt is used as an intermediate used in the preparation, and is prepared by reacting a compound of formula A with a compound of formula B.

화학식 C의 화합물의 제조방법은 하기 반응식 2로 나타낼 수 있다.The preparation method of the compound of formula C can be represented by the following scheme 2.

[반응식 2][Scheme 2]

Figure 112019071648864-pat00012
Figure 112019071648864-pat00012

화학식 A의 화합물은 하기 화학식 a-1의 화합물과 하기 화학식 a-2의 화합물을 반응시켜 제조할 수 있다.The compound of formula A can be prepared by reacting a compound of formula a-1 with a compound of formula a-2.

[화학식 a-1][Formula a-1]

Figure 112019071648864-pat00013
(이때, R1은 C1-C6알킬을 나타낸다)
Figure 112019071648864-pat00013
(At this time, R 1 represents C 1 -C 6 alkyl)

[화학식 a-2][Formula a-2]

Figure 112019071648864-pat00014
(이때, R3는 -O-(C1-C5알킬), Cl 또는 Br을 나타낸다)
Figure 112019071648864-pat00014
(At this time, R 3 represents -O-(C 1 -C 5 alkyl), Cl or Br)

화학식 a-1의 화합물은 하기 화학식 a-3의 화합물을 이용하여 제조할 수 있다.The compound of Formula a-1 can be prepared using the compound of Formula a-3 below.

[화학식 a-3][Formula a-3]

Figure 112019071648864-pat00015
Figure 112019071648864-pat00015

화학식 a-3의 화합물을 에스터화시켜 화학식 a-1의 화합물을 제조할 수 있다.The compound of formula a-1 can be prepared by esterifying the compound of formula a-3.

화학식 A의 화합물의 제조방법은 하기 반응식 3으로 나타낼 수 있다.The preparation method of the compound of formula A can be represented by the following Scheme 3.

[반응식 3][Scheme 3]

Figure 112019071648864-pat00016
Figure 112019071648864-pat00016

화학식 B의 화합물은 하기 화학식 b-1의 화합물과 하기 화학식 b-2의 화합물을 반응시켜 화학식 b-3의 화합물을 제조하고, 화학식 b-3의 화합물을 할로겐화시켜 제조할 수 있다.The compound of formula B can be prepared by reacting a compound of formula b-1 with a compound of formula b-2 to prepare a compound of formula b-3, and halogenating the compound of formula b-3.

[화학식 b-1][Formula b-1]

Figure 112019071648864-pat00017
Figure 112019071648864-pat00017

[화학식 b-2][Formula b-2]

Figure 112019071648864-pat00018
Figure 112019071648864-pat00018

[화학식 b-3][Formula b-3]

Figure 112019071648864-pat00019
Figure 112019071648864-pat00019

화학식 B의 화합물의 제조방법은 하기 반응식 4로 나타낼 수 있다.The preparation method of the compound of Formula B can be represented by the following Scheme 4.

[반응식 4][Scheme 4]

Figure 112019071648864-pat00020
Figure 112019071648864-pat00020

반응식 4에 따르면, 출발물질로서 화학식 b-1의 화합물을 화학식 b-2의 화합물과 프리델-크래프트 아실화 반응시켜 화학식 b-3의 화합물을 제조한 후, 할로겐화 반응을 통해 화학식 B의 화합물을 제조할 수 있다.According to Scheme 4, a compound of formula b-1 as a starting material is subjected to a Friedel-Craft acylation reaction with a compound of formula b-2 to prepare a compound of formula b-3, and then a compound of formula B is prepared through a halogenation reaction. can do.

본 발명의 (3R,5R)-7-[2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-[(4-히드록시메틸페닐아미노)카보닐]-피롤-1-일]-3,5-디히드록시 헵탄산 헤미칼슘염의 제조방법에 따르면, 화합물의 주요 구조부들 각각을 개별적으로 합성한 후 커플링하는 수렴합성 방식으로 수행되므로, 종래문헌에 개시된 순차합성 방식에 비해 주요 유연물질의 제어가 용이한 장점이 있다. 또한, 본 발명은, 순차합성 경로가 내재하고 있는 위험요소(합성 중간에 실패 시 처음 경로로 돌아가서 합성을 반복해야 하는 등)를 줄여 제조시간을 단축시킬 수 있다.(3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxymethylphenylamino)carbonyl]-pyrrole-1- of the present invention In accordance with the method for preparing the hemicalcium salt of general]-3,5-dihydroxy heptanoic acid, since each of the major structural parts of the compound is individually synthesized and then coupled, it is performed in a convergent synthesis method, so that the sequential synthesis method disclosed in the prior literature Compared to that, there is an advantage in that it is easy to control major related substances. In addition, the present invention can shorten the manufacturing time by reducing the risk factors inherent in the sequential synthesis pathway (such as having to return to the first route and repeat the synthesis when the synthesis fails in the middle of synthesis).

이하, 구체적인 실시예들을 통하여 본 발명에 대해서 상세히 설명하기로 한다. 다르게 정의되지 않는 한, 기술적이거나 과학적인 용어를 포함해서 여기서 사용되는 모든 용어들은 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자에 의해 일반적으로 이해되는 것과 동일한 의미를 가지고 있다. 일반적으로 사용되는 사전에 정의되어 있는 것과 같은 용어들은 관련 기술의 문맥 상 가지는 의미와 일치하는 의미를 가지는 것으로 해석되어야 하며, 본 출원에서 명백하게 정의하지 않는 한, 이상적이거나 과도하게 형식적인 의미로 해석되지 않는다.Hereinafter, the present invention will be described in detail through specific embodiments. Unless otherwise defined, all terms used herein, including technical or scientific terms, have the same meaning as commonly understood by one of ordinary skill in the art to which the present invention belongs. Terms as defined in a commonly used dictionary should be interpreted as having a meaning consistent with the meaning in the context of the related technology, and should not be interpreted as an ideal or excessively formal meaning unless explicitly defined in this application. Does not.

실시예 1: 메틸 4-(2-(2-(4-플루오로페닐)-2-옥소-1-페닐에틸)-4-메틸-3-옥소펜탄아미도)벤조에이트의 제조Example 1: Preparation of methyl 4-(2-(2-(4-fluorophenyl)-2-oxo-1-phenylethyl)-4-methyl-3-oxopentanamido)benzoate

(단계 1-1): 메틸 4-아미노벤조에이트의 제조(Step 1-1): Preparation of methyl 4-aminobenzoate

4-아미노벤조산(120 g, 1.0 eq)을 메탄올(1.2 L)에 묽힌 후, 0 ~ 5℃에서 교반하여 용해시켰다. SOCl2(125 g, 1.2 eq)를 천천히 넣고 서서히 온도를 올려 환류하면서 2시간 동안 교반하였다. 반응종결 확인 후, 20 ~ 25℃로 냉각하고 감압 건조시킨 후, 물(1.2 L)을 넣어교반하였다. 0 ~ 5℃에서 pH 8이 되도록 탄산수소나트륨 수용액을 가하여 고체로 만든 후, 물(1.2 L)을 넣어30분 동안 교반하였다. 생성된 고체를 물로 충분히 세척하여 여과한 후, 50℃에서 16시간 동안 진공 건조하여 메틸 4-아미노벤조에이트를 얻었다.After diluting 4-aminobenzoic acid (120 g, 1.0 eq) in methanol (1.2 L), it was dissolved by stirring at 0 to 5°C. SOCl 2 (125 g, 1.2 eq) was slowly added thereto, and the temperature was gradually raised to reflux and stirred for 2 hours. After confirming the completion of the reaction, the mixture was cooled to 20 ~ 25°C and dried under reduced pressure, followed by adding water (1.2 L) and stirring. After adding an aqueous sodium hydrogen carbonate solution to a pH of 8 at 0 to 5°C to make a solid, water (1.2 L) was added and stirred for 30 minutes. The resulting solid was sufficiently washed with water, filtered, and dried under vacuum at 50° C. for 16 hours to obtain methyl 4-aminobenzoate.

고체 128 g(수율 96.8%) 수분함량 0.7%(< 1.0%)Solid 128 g (yield 96.8%) moisture content 0.7% (< 1.0%)

(단계 1-2): 메틸 4-(4-메틸-3-옥소펜탄아미도)벤조에이트의 제조(Step 1-2): Preparation of methyl 4-(4-methyl-3-oxopentanamido)benzoate

상기 단계 1-1에서 수득한 메틸 4-아미노벤조에이트(80 g, 1.003 eq)과 메틸 4-메틸-3-옥소펜타노에이트(76 g, 1.0 eq)을 톨루엔(0.76 L)에 묽힌 후, 상온에서 교반하여 용해시켰다. 반응용액을 Dean-stark 트랩을 이용하여 하루 동안 환류하여 수분을 제거하였다. 반응종결 확인 후, 20 ~ 25℃로 냉각하고 감압 건조시킨 후, 에틸아세테이트(0.76 L)을 넣어 녹인 후, 유기층을 20% 염산수용액을 이용하여 2회 세척하였다. 추출한 유기층은 물(0.15 L)과 10% 탄산수소나트륨 수용액(0.15 L)과 포화 염화나트륨 수용액(0.06 L)으로 세척하고, 황산마그네슘을 넣어 건조시킨 후, 여과하였다. 여과액은 감압 건조한 뒤 헵탄(0.76 L)을 넣어 상온에서 10시간 교반하여 고체를 생성시켰다. 생성된 고체를 헵탄으로 충분히 세척하여 여과하였다. 50℃에서 16시간 동안 진공 건조하여 메틸 4-(4-메틸-3-옥소펜탄아미도)벤조에이트를 얻었다.After diluting methyl 4-aminobenzoate (80 g, 1.003 eq) and methyl 4-methyl-3-oxopentanoate (76 g, 1.0 eq) obtained in step 1-1 in toluene (0.76 L), It was dissolved by stirring at room temperature. The reaction solution was refluxed for one day using a Dean-stark trap to remove moisture. After confirming the completion of the reaction, the mixture was cooled to 20 ~ 25°C, dried under reduced pressure, and dissolved in ethyl acetate (0.76 L), and the organic layer was washed twice with 20% aqueous hydrochloric acid solution. The extracted organic layer was washed with water (0.15 L), 10% aqueous sodium hydrogen carbonate solution (0.15 L) and saturated aqueous sodium chloride solution (0.06 L), dried with magnesium sulfate, and filtered. After drying the filtrate under reduced pressure, heptane (0.76 L) was added and stirred at room temperature for 10 hours to generate a solid. The resulting solid was thoroughly washed with heptane and filtered. Vacuum-dried at 50° C. for 16 hours to obtain methyl 4-(4-methyl-3-oxopentanamido)benzoate.

고체 118.3 g(수율 85%)118.3 g of solid (85% yield)

1H NMR(500 MHz, DMSO-d6) 10.40(NH, br s, 1H), 7.92(d, J = 8.5 Hz, 2H), 7.71(d, J = 8.5 Hz, 2H), 3.82(s, 3H), 3.67(s, 2H), 2.75(sep, J = 7.0 Hz, 1H), 1.05(d, J = 7.0 Hz, 6H), MH+ 264. 1 H NMR (500 MHz, DMSO-d 6 ) 10.40 (NH, br s, 1H), 7.92 (d, J = 8.5 Hz, 2H), 7.71 (d, J = 8.5 Hz, 2H), 3.82 (s, 3H), 3.67 (s, 2H), 2.75 (sep, J = 7.0 Hz, 1H), 1.05 (d, J = 7.0 Hz, 6H), MH+ 264.

(단계 1-3): 2-브로모-1-(4-플루오로페닐)-2-페닐에탄-1-온의 제조(Step 1-3): Preparation of 2-bromo-1-(4-fluorophenyl)-2-phenylethan-1-one

단계 a: 1-(4-플루오로페닐)-2-페닐에탄-1-온의 제조Step a: Preparation of 1-(4-fluorophenyl)-2-phenylethan-1-one

플루오로벤젠(100 g)을 0℃에서 질소 하에 반응기에 넣은 후, 암모늄 클로라이드(103 g)를 추가하였다. -10℃로 냉각하여, 페닐아세틸클로라이드(110.75 g)를적가한 후, 2시간 동안 교반하였다. 반응용액에 얼음물(600 g)과 염산(0.03 L)을추가하여 반응을 종결하였다. 메틸렌클로라이드(1 L)를 넣어 유기층을 분리하고, 수성층은 메틸렌클로라이드(0.5 L)를 이용하여 한번 더 세척하였다. 추출한 유기층은 5% 탄산수소나트륨 수용액(0.6 L)과 5% 포화 염화나트륨 수용액(0.4 L)으로 세척하고, 황산마그네슘을 넣어 건조시킨 후, 셀라이트로 여과하였다. 여과액을 반응기에 넣어 건조시켜 1-(4-플루오로페닐)-2-페닐에탄-1-온을 얻었다.After fluorobenzene (100 g) was placed in a reactor under nitrogen at 0° C., ammonium chloride (103 g) was added. After cooling to -10°C, phenylacetyl chloride (110.75 g) was added dropwise, followed by stirring for 2 hours. The reaction was terminated by adding ice water (600 g) and hydrochloric acid (0.03 L) to the reaction solution. Methylene chloride (1 L) was added to separate the organic layer, and the aqueous layer was washed once more with methylene chloride (0.5 L). The extracted organic layer was washed with 5% aqueous sodium hydrogen carbonate solution (0.6 L) and 5% saturated aqueous sodium chloride solution (0.4 L), dried with magnesium sulfate, and then filtered through Celite. The filtrate was put in a reactor and dried to obtain 1-(4-fluorophenyl)-2-phenylethan-1-one.

고체 150 g(수율 98%) 150 g of solid (98% yield)

1H NMR(500 MHz, DMSO-d6) 8.15-8.11(m, 2H), 7.39-7.34(m, 2H), 7.33-7.30(m, 2H), 7.27-7.21(m, 3H), 4.39(s, 2H), MH+ 215 1 H NMR (500 MHz, DMSO-d 6 ) 8.15-8.11 (m, 2H), 7.39-7.34 (m, 2H), 7.33-7.30 (m, 2H), 7.27-7.21 (m, 3H), 4.39 ( s, 2H), MH+ 215

단계 b: 2-브로모-1-(4-플루오로페닐)-2-페닐에탄-1-온의 제조Step b: Preparation of 2-bromo-1-(4-fluorophenyl)-2-phenylethan-1-one

브로민(109 g)을메틸렌클로라이드(0.2 L)에묽힌후, 상기 단계 a에서 얻은 1-(4-플루오로페닐)-2-페닐에탄-1-온에적가하여 10분간교반하였다. 15℃로 냉각하여 5% 황산나트륨(0.4 L)과 메틸렌클로라이드를 넣어유기층을 분리하였다. 추출한 유기층을 5% 탄산수소나트륨 수용액(0.4 L)과 5% 포화 염화나트륨 수용액으로 세척하여 감압 농축하였다. 농축액을 헥산(2 L)에 묽혀 슬러리로 만든 후, 하루 동안 방치하였다. 생성된 고체를 여과하여 50℃에서 4시간 동안 진공 건조하여 2-브로모-1-(4-플루오로페닐)-2-페닐에탄-1-온을 얻었다.Bromine (109 g) was diluted in methylene chloride (0.2 L), added dropwise to 1-(4-fluorophenyl)-2-phenylethan-1-one obtained in step a, and stirred for 10 minutes. After cooling to 15° C., 5% sodium sulfate (0.4 L) and methylene chloride were added to separate the organic layer. The extracted organic layer was washed with 5% aqueous sodium hydrogen carbonate solution (0.4 L) and 5% saturated aqueous sodium chloride solution, and then concentrated under reduced pressure. The concentrate was diluted in hexane (2 L) to make a slurry, and then left to stand for one day. The resulting solid was filtered and dried under vacuum at 50° C. for 4 hours to obtain 2-bromo-1-(4-fluorophenyl)-2-phenylethan-1-one.

고체 171 g(수율 81.4%)171 g of solid (81.4% yield)

1H NMR(500 MHz, DMSO-d6): 8.18-8.14(m, 2H), 7.55-7.53(m, 2H), 7.40-7.31(m, 5H), 7.18(s, 1H). 1 H NMR (500 MHz, DMSO-d 6 ): 8.18-8.14 (m, 2H), 7.55-7.53 (m, 2H), 7.40-7.31 (m, 5H), 7.18 (s, 1H).

(단계 1-4): 메틸 4-(2-(2-(4-플루오로페닐)-2-옥소-1-페닐에틸)-4-메틸-3-옥소펜탄아미도)벤조에이트의 제조(Step 1-4): Preparation of methyl 4-(2-(2-(4-fluorophenyl)-2-oxo-1-phenylethyl)-4-methyl-3-oxopentanamido)benzoate

상기 단계 1-2에서 수득한 메틸 4-(4-메틸-3-옥소펜탄아미도)벤조에이트(167 g)를 아세톤(600 g)에 묽힌 뒤, 20℃에서 탄산칼륨(131.5 g)를 넣어 교반하였다. 18℃로 냉각한 후, 아세톤(0.2 L)에 묽힌 상기 단계 1-3에서 수득한 2-브로모-1-(4-플루오로페닐)-2-페닐에탄-1-온(BFPE, 186 g)을 적가하고, 반응용액을 6시간 동안 교반한 후, 여과하여 건조시켰다. 농축액을 에틸아세테이트(1.6 L)와 증류수(0.8 L)로 세척하고, 수성층은 에틸아세테이트(0.3 L)로 한 번 더 씻어냈다. 추출한 유기층을 감압 농축한 뒤, 메탄올:증류수=9:1 용액(v:v 1.25 L)에 묽혀 깨끗하게 녹을 때까지 환류하였다. 반응용액을 0 ~ 5℃로 냉각하여 2시간 동안 교반한 후, 차갑게 식힌 메탄올:증류수=9:1 용액(0.167 L)과 얼음물(0.167 L)로 세척하여 여과하였다. 여과물을 헥산(0.835 L)으로 묽혀 슬러리로 만든 후, 하루 동안 50℃에서 진공 건조하여 메틸 4-(2-(2-(4-플루오로페닐)-2-옥소-1-페닐에틸)-4-메틸-3-옥소펜탄아미도)벤조에이트를 수득하였다.After diluting the methyl 4-(4-methyl-3-oxopentanamido)benzoate (167 g) obtained in step 1-2 in acetone (600 g), potassium carbonate (131.5 g) was added at 20°C. Stirred. After cooling to 18° C., 2-bromo-1-(4-fluorophenyl)-2-phenylethan-1-one (BFPE, 186 g) obtained in step 1-3 diluted in acetone (0.2 L) ) Was added dropwise, and the reaction solution was stirred for 6 hours, filtered and dried. The concentrate was washed with ethyl acetate (1.6 L) and distilled water (0.8 L), and the aqueous layer was washed once more with ethyl acetate (0.3 L). The extracted organic layer was concentrated under reduced pressure, diluted in a methanol:distilled water = 9:1 solution (v:v 1.25 L) and refluxed until cleanly dissolved. The reaction solution was cooled to 0 ~ 5°C, stirred for 2 hours, washed with cold methanol:distilled water=9:1 solution (0.167 L) and ice water (0.167 L) and filtered. The filtrate was diluted with hexane (0.835 L) to make a slurry, and then dried in vacuo at 50° C. for one day to obtain methyl 4-(2-(2-(4-fluorophenyl)-2-oxo-1-phenylethyl)- 4-methyl-3-oxopentanamido)benzoate was obtained.

고체 224 g(수율 74.3%)224 g of solid (74.3% yield)

1H NMR(500 MHz, DMSO-d6) 10.52(NH, br s, 1H), 8.15-8.11(m, 2H), 7.84(d, J = 9.0 Hz, 2H), 7.47(d, J = 9.0 Hz, 2H), 7.35(d, J = 7.5 Hz, 2H), 7.33-7.30(m, 2H), 7.24-7.21(m, 3H), 5.43(d, J = 11.0 Hz, 1H), 4.91(d, J = 11.0 Hz, 1H), 3.80(s, 3H), 2.90(sep, J = 7.0 Hz, 1H), 1.17(d, J = 7.0 Hz, 3H), 0.93(d, J = 7.0 Hz, 3H), MH+ 476. 1 H NMR (500 MHz, DMSO-d 6 ) 10.52 (NH, br s, 1H), 8.15-8.11 (m, 2H), 7.84 (d, J = 9.0 Hz, 2H), 7.47 (d, J = 9.0 Hz, 2H), 7.35 (d, J = 7.5 Hz, 2H), 7.33-7.30 (m, 2H), 7.24-7.21 (m, 3H), 5.43 (d, J = 11.0 Hz, 1H), 4.91 (d , J = 11.0 Hz, 1H), 3.80 (s, 3H), 2.90 (sep, J = 7.0 Hz, 1H), 1.17 (d, J = 7.0 Hz, 3H), 0.93 (d, J = 7.0 Hz, 3H) ), MH+ 476.

실시예 2: 메틸 4-(2-(2-(4-플루오로페닐)-2-옥소-1-페닐에틸)-4-메틸-3-옥소펜탄아미도)벤조에이트의 제조Example 2: Preparation of methyl 4-(2-(2-(4-fluorophenyl)-2-oxo-1-phenylethyl)-4-methyl-3-oxopentanamido)benzoate

(단계 2-1): 2-클로로-1-(4-플루오로페닐)-2-페닐에탄-1-온의 제조 (Step 2-1): Preparation of 2-chloro-1-(4-fluorophenyl)-2-phenylethan-1-one

염화설퍼릴(100 g)을염화칼슘 가드 튜브 하에 첨가하였다. 단계 1-3에서의 단계 a와 실질적으로 동일한 공정을 통해 수득한 1-(4-플루오로페닐)-2-페닐에탄-1-온(150 g)을 메틸렌클로라이드(0.23 L)로 묽혀 10 ~ 15℃에서 4분간 적가하였다. 이후, 상온에서 2.5시간 동안 교반한 후, 반응용액에 얼음물(900 g)을 추가하여 반응을 종결하였다. 메틸렌클로라이드(0.6 L)에묽힌후, 유기층을 5% 탄산수소나트륨 수용액(0.3 L)과 5% 포화 염화나트륨 수용액(0.3 L)으로 세척하고, 황산마그네슘을 넣어 건조시킨 후, 셀라이트로 여과하였다. 여과액은 감압 건조한 뒤 진공 건조하여 2-클로로-1-(4-플루오로페닐)-2-페닐에탄-1-온을 얻었다.Sulfuryl chloride (100 g) was added under a calcium chloride guard tube. 1-(4-fluorophenyl)-2-phenylethan-1-one (150 g) obtained through substantially the same process as step a in step 1-3 was diluted with methylene chloride (0.23 L) to 10 ~ It was added dropwise at 15° C. for 4 minutes. Then, after stirring at room temperature for 2.5 hours, ice water (900 g) was added to the reaction solution to terminate the reaction. After diluting in methylene chloride (0.6 L), the organic layer was washed with 5% aqueous sodium hydrogen carbonate solution (0.3 L) and 5% saturated aqueous sodium chloride solution (0.3 L), dried with magnesium sulfate, and filtered through celite. The filtrate was dried under reduced pressure and then vacuum dried to obtain 2-chloro-1-(4-fluorophenyl)-2-phenylethan-1-one.

고체 156 g(수율 90%)156 g solid (90% yield)

1H NMR(500 MHz, DMSO-d6) 8.15-8.11(m, 2H), 7.50-7.47(m, 2H), 7.40-7.31(m, 5H), 7.13(s, 1H). 1 H NMR (500 MHz, DMSO-d 6 ) 8.15-8.11 (m, 2H), 7.50-7.47 (m, 2H), 7.40-7.31 (m, 5H), 7.13 (s, 1H).

(단계 2-2): 메틸 4-(2-(2-(4-플루오로페닐)-2-옥소-1-페닐에틸)-4-메틸-3-옥소펜탄아미도)벤조에이트의 제조(Step 2-2): Preparation of methyl 4-(2-(2-(4-fluorophenyl)-2-oxo-1-phenylethyl)-4-methyl-3-oxopentanamido)benzoate

상기 단계 1-2에서 수득한 메틸 4-(4-메틸-3-옥소펜탄아미도)벤조에이트(110 g)를 아세톤(0.66 L)에 묽힌 뒤, 20 ~ 25℃에서 탄산칼륨(86.6 g)를 넣어 교반하였다. 같은 온도를 유지하면서 아세톤(0.22 L)에 묽힌 2-클로로-1-(4-플루오로페닐)-2-페닐에탄-1-온(CFPE, 104 g)을 적가하였다. 반응용액을 8시간 동안 환류한 후, 20 ~ 25℃로 냉각하여 여과하였다. 여과액을 농축하여 에틸아세테이트(1.0 L)와 증류수(0.5 L)에 묽혀 10분간 교반한 후 세척하였다. 수성층은 에틸아세테이트(0.18 L)로 한 번 더 씻어냈다. 추출한 유기층을 감압 농축한 뒤, 메탄올:증류수=4:1 용액(v:v, 0.55 L)에 묽혀 1시간 동안 환류하였다. 반응용액을 0 ~ 5℃로 천천히 냉각하여 2시간 동안 교반한 후, 메탄올:증류수=4:1 용액(0.11 L)과 얼음물(0.11 L)로 세척하여 여과하였다. 여과물을 헥산(0.55 L)으로 묽혀 슬러리로 만든 후, 8시간 동안 50℃에서 진공 건조하여, 메틸 4-(2-(2-(4-플루오로페닐)-2-옥소-1-페닐에틸)-4-메틸-3-옥소펜탄아미도)벤조에이트를 얻었다.After diluting the methyl 4-(4-methyl-3-oxopentanamido)benzoate (110 g) obtained in step 1-2 in acetone (0.66 L), potassium carbonate (86.6 g) at 20 to 25°C And stirred. Dilute 2-chloro-1-(4-fluorophenyl)-2-phenylethan-1-one (CFPE, 104 g) was added dropwise to acetone (0.22 L) while maintaining the same temperature. The reaction solution was refluxed for 8 hours, cooled to 20 ~ 25°C, and filtered. The filtrate was concentrated, diluted with ethyl acetate (1.0 L) and distilled water (0.5 L), stirred for 10 minutes, and washed. The aqueous layer was washed once more with ethyl acetate (0.18 L). The extracted organic layer was concentrated under reduced pressure, diluted in methanol:distilled water = 4:1 solution (v:v, 0.55 L) and refluxed for 1 hour. The reaction solution was slowly cooled to 0 ~ 5°C, stirred for 2 hours, washed with methanol:distilled water=4:1 solution (0.11 L) and ice water (0.11 L) and filtered. The filtrate was diluted with hexane (0.55 L) to make a slurry, and then dried under vacuum at 50° C. for 8 hours, and methyl 4-(2-(2-(4-fluorophenyl)-2-oxo-1-phenylethyl) )-4-methyl-3-oxopentanamido)benzoate was obtained.

고체 157 g(수율 79%)157 g of solid (79% yield)

1H NMR(500 MHz, DMSO-d6) 10.52(NH, br s, 1H), 8.15-8.11(m, 2H), 7.84(d, J = 9.0 Hz, 2H), 7.47(d, J = 9.0 Hz, 2H), 7.35(d, J = 7.5 Hz, 2H), 7.33-7.30(m, 2H), 7.24-7.21(m, 3H), 5.43(d, J = 11.0 Hz, 1H), 4.91(d, J = 11.0 Hz, 1H), 3.80(s, 3H), 2.90(sep, J = 7.0 Hz, 1H), 1.17(d, J = 7.0 Hz, 3H), 0.93(d, J = 7.0 Hz, 3H), MH+ 476. 1 H NMR (500 MHz, DMSO-d 6 ) 10.52 (NH, br s, 1H), 8.15-8.11 (m, 2H), 7.84 (d, J = 9.0 Hz, 2H), 7.47 (d, J = 9.0 Hz, 2H), 7.35 (d, J = 7.5 Hz, 2H), 7.33-7.30 (m, 2H), 7.24-7.21 (m, 3H), 5.43 (d, J = 11.0 Hz, 1H), 4.91 (d , J = 11.0 Hz, 1H), 3.80 (s, 3H), 2.90 (sep, J = 7.0 Hz, 1H), 1.17 (d, J = 7.0 Hz, 3H), 0.93 (d, J = 7.0 Hz, 3H) ), MH+ 476.

실시예 3: (3R,5R)-7-(2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-((4-히드록시 메틸 페닐 아미노)카보닐)-피롤-1-일)-3,5-디히드록시 헵탄산 헤미칼슘염의 제조Example 3: (3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-((4-hydroxy methyl phenyl amino)carbonyl)-pyrrole- 1-yl)-3,5-dihydroxyheptanoic acid hemicalcium salt preparation

(단계 3-1) 메틸 4-(1-(2-((4R,6R)-6-(2-(tert-부톡시)-2-옥소에틸)-2,2-디메틸-1,3-디옥산-4-일)에틸)-5-(4-플루오로페닐)-2-아이소프로필-4-페닐-1H-피롤-3-카복시아미도)벤조에이트의 제조(Step 3-1) Methyl 4-(1-(2-((4R,6R)-6-(2-(tert-butoxy)-2-oxoethyl)-2,2-dimethyl-1,3- Preparation of dioxan-4-yl)ethyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxyamido)benzoate

실시예 1에 따라 얻어진 메틸 4-(2-(2-(4-플루오로페닐)-2-옥소-1-페닐에틸)-4-메틸-3-옥소펜탄아미도)벤조에이트(800 g)과 tert-부틸 2-((4R,6R)-6-(2-아미노에틸)-2,2-디메틸-1,3-디옥산-4-일)아세테이트(552.5 g)와 피발산(177.2 g)을 헵테인(6.72 L), 톨루엔(2.4 L), 테트라하이드로퓨란(2.4 L)에 묽혔다. 반응용액을 Dean-stark 트랩을 이용하여 하루 동안 환류하여, 수분을 제거하였다. 반응용액을 상온으로 냉각하여 감압 농축하였다. 농축액을 에틸아세테이트(8.0 L)에 녹여 교반한 후, 증류수(4 L)로 2회 씻어냈다. 추출된 유기층을 감압 농축하여 고체를 얻은 후, 아이소프로필 알코올(4 L)에 묽혀 50℃에서 1시간 동안 슬러리화하였다. 반응물에 헥산(4 L)을 넣어 동일 온도에서 추가로 1시간 동안 슬러리화하였다. 반응물을 상온으로 냉각하여 1시간 더 교반하였다. 생성된 고체를 여과한 후, 헥산(4 L)을 이용하여 2회 세척하여 50℃에서 하루 동안 건조하여, 메틸 4-(1-(2-((4R,6R)-6-(2-(tert-부톡시)-2-옥소에틸)-2,2-디메틸-1,3-디옥산-4-일)에틸)-5-(4-플루오로페닐)-2-아이소프로필-4-페닐-1H-피롤-3-카복시아미도)벤조에이트를 얻었다.Methyl 4-(2-(2-(4-fluorophenyl)-2-oxo-1-phenylethyl)-4-methyl-3-oxopentanamido)benzoate (800 g) obtained according to Example 1 And tert-butyl 2-((4R,6R)-6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate (552.5 g) and pivalic acid (177.2 g ) Was diluted in heptane (6.72 L), toluene (2.4 L) and tetrahydrofuran (2.4 L). The reaction solution was refluxed for one day using a Dean-stark trap to remove moisture. The reaction solution was cooled to room temperature and concentrated under reduced pressure. The concentrated solution was dissolved in ethyl acetate (8.0 L), stirred, and washed twice with distilled water (4 L). After the extracted organic layer was concentrated under reduced pressure to obtain a solid, it was diluted with isopropyl alcohol (4 L) and slurried at 50° C. for 1 hour. Hexane (4 L) was added to the reaction product, and the mixture was slurried for an additional hour at the same temperature. The reaction was cooled to room temperature and stirred for an additional hour. After filtering the resulting solid, washed twice with hexane (4 L) and dried at 50° C. for one day, methyl 4-(1-(2-((4R,6R)-6-(2-( tert-butoxy)-2-oxoethyl)-2,2-dimethyl-1,3-dioxan-4-yl)ethyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl -1H-pyrrole-3-carboxyamido)benzoate was obtained.

고체 845.5 g(수율 70.5%)845.5 g of solid (70.5% yield)

1H NMR(500 MHz, DMSO-d6) 10.17(NH, br s, 1H), 7.83(d, J = 9.0 Hz, 2H), 7.64(d, J = 8.0 Hz, 2H), 7.28-7.25(m, 2H), 7.20(t, J = 9.0 Hz, 2H), 7.08-7.03(m, 4H), 7.01-6.97(m, 1H), 4.13-4.08(m, 1H), 3.95-3.89(m, 1H), 3.80(s, 3H), 3.80-3.74(m, 2H), 3.25-3.19(m, 1H), 2.30(dd, J = 15.0 Hz, 5.0 Hz, 1H), 2.17(dd, J = 15.0 Hz, 8.0 Hz, 1H), 1.64-1.50(m, 2H), 1.38(s, 9H), 1.36(d, J = 7.0 Hz, 6H), 1.35-1.30(m, 1H), 1.31(s, 3H), 1.16(s, 3H), 0.92(q, J = 12.0 Hz, 1H), MH- 711. 1 H NMR (500 MHz, DMSO-d 6 ) 10.17 (NH, br s, 1H), 7.83 (d, J = 9.0 Hz, 2H), 7.64 (d, J = 8.0 Hz, 2H), 7.28-7.25 ( m, 2H), 7.20 (t, J = 9.0 Hz, 2H), 7.08-7.03 (m, 4H), 7.01-6.97 (m, 1H), 4.13-4.08 (m, 1H), 3.95-3.89 (m, 1H), 3.80 (s, 3H), 3.80-3.74 (m, 2H), 3.25-3.19 (m, 1H), 2.30 (dd, J = 15.0 Hz, 5.0 Hz, 1H), 2.17 (dd, J = 15.0 Hz, 8.0 Hz, 1H), 1.64-1.50 (m, 2H), 1.38 (s, 9H), 1.36 (d, J = 7.0 Hz, 6H), 1.35-1.30 (m, 1H), 1.31 (s, 3H) ), 1.16 (s, 3H), 0.92 (q, J = 12.0 Hz, 1H), MH-711.

(단계 3-2): 4-(1-(2-((4R,6R)-6-(2-(tert-부톡시)-2-옥소에틸)-2,2-디메틸-1,3-디옥산 -4-일)에틸)-5-(4-플루오로페닐)-2-아이소프로필-4-페닐-1H-피롤-3-카복시아미도) 벤조산의 제조(Step 3-2): 4-(1-(2-((4R,6R)-6-(2-(tert-butoxy)-2-oxoethyl)-2,2-dimethyl-1,3- Preparation of dioxane -4-yl)ethyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxyamido) benzoic acid

상기 단계 3-1에서 얻은 메틸 4-(1-(2-((4R,6R)-6-(2-(tert-부톡시)-2-옥소에틸)-2,2-디메틸-1,3-디옥산-4-일)에틸)-5-(4-플루오로페닐)-2-아이소프로필-4-페닐-1H-피롤-3-카복시아미도)벤조에이트(700 g)을 아세토니트릴(7 L)에 묽힌 후 교반하였다. 수산화나트륨(98.3 g)을 증류수(2.1 L)에 묽혀 반응용액에 적가한 후, 50℃에서 5시간 동안 교반하였다. 반응용액을 상온으로 냉각하여 증류수(7 L)을 넣어 반응을 종결하였다. 반응용액에 20% 아세트산 수용액(아세트산 0.263 L, 증류수 1.05 L)을 적가하여 pH 5.5 ~ 6.0로 맞춘 후, 상온에서 3시간 동안 교반하였다. 생성된 고체를 여과시킨 후, 증류수(2.8 L)로 4회 세척하고, 추가로 아세토니트릴(2.1 L)로 2회 세척하였다. 생성된 고체를 95% 에탄올(3.5 L)에 묽힌 후, 1시간 동안 환류하고, 반응용액을 상온으로 냉각하여 3시간 동안 교반하였다. 생성된 고체는 여과하여 50℃에서 하루 동안 진공 건조하여 4-(1-(2-((4R,6R)-6-(2-(tert-부톡시)-2-옥소에틸)-2,2-디메틸-1,3-디옥산 -4-일)에틸)-5-(4-플루오로페닐)-2-아이소프로필-4-페닐-1H-피롤-3-카복시아미도) 벤조산을 얻었다.Methyl 4-(1-(2-((4R,6R)-6-(2-(tert-butoxy)-2-oxoethyl)-2,2-dimethyl-1,3 obtained in step 3-1 above -Dioxan-4-yl)ethyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxyamido)benzoate (700 g) was added to acetonitrile ( It was diluted in 7 L) and stirred. Sodium hydroxide (98.3 g) was diluted in distilled water (2.1 L) and added dropwise to the reaction solution, followed by stirring at 50° C. for 5 hours. The reaction solution was cooled to room temperature and distilled water (7 L) was added to terminate the reaction. A 20% aqueous acetic acid solution (0.263 L of acetic acid, 1.05 L of distilled water) was added dropwise to the reaction solution to adjust the pH to 5.5 to 6.0, followed by stirring at room temperature for 3 hours. The resulting solid was filtered, washed 4 times with distilled water (2.8 L), and further washed twice with acetonitrile (2.1 L). The resulting solid was diluted in 95% ethanol (3.5 L), refluxed for 1 hour, and the reaction solution was cooled to room temperature and stirred for 3 hours. The resulting solid was filtered and dried under vacuum at 50° C. for one day to obtain 4-(1-(2-((4R,6R)-6-(2-(tert-butoxy)-2-oxoethyl)-2,2 -Dimethyl-1,3-dioxane -4-yl)ethyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxyamido)benzoic acid was obtained.

고체 790 g(수율 71.5%)790 g of solid (71.5% yield)

1H NMR(500 MHz, DMSO-d6) 10.13(NH, br s, 1H), 7.80(d, J = 8.5 Hz, 2H), 7.62(d, J = 9.0 Hz, 2H), 7.28-7.25(m, 2H), 7.22-7.18(m, 2H), 7.08-7.04(m, 4H), 7.01-6.98(m, 1H), 4.13-4.08(m, 1H), 3.96-3.89(m, 1H), 3.81-3.75(m, 2H), 3.22(sep, J = 7.0 Hz, 1H), 2.30(dd, J = 15.0 Hz, 5.0 Hz, 1H), 2.18(dd, J = 15.0 Hz, 8.0 Hz, 1H), 1.64-1.50(m, 2H), 1.38(s, 9H), 1.36(d, J = 7.0 Hz, 6H), 1.36-1.30(m, 1H), 1.31(s, 3H), 1.16(s, 3H), 0.93(q, J = 12.0 Hz, 1H), MH- 698. 1 H NMR (500 MHz, DMSO-d 6 ) 10.13 (NH, br s, 1H), 7.80 (d, J = 8.5 Hz, 2H), 7.62 (d, J = 9.0 Hz, 2H), 7.28-7.25 ( m, 2H), 7.22-7.18 (m, 2H), 7.08-7.04 (m, 4H), 7.01-6.98 (m, 1H), 4.13-4.08 (m, 1H), 3.96-3.89 (m, 1H), 3.81-3.75 (m, 2H), 3.22 (sep, J = 7.0 Hz, 1H), 2.30 (dd, J = 15.0 Hz, 5.0 Hz, 1H), 2.18 (dd, J = 15.0 Hz, 8.0 Hz, 1H) , 1.64-1.50(m, 2H), 1.38(s, 9H), 1.36(d, J = 7.0 Hz, 6H), 1.36-1.30(m, 1H), 1.31(s, 3H), 1.16(s, 3H) ), 0.93 (q, J = 12.0 Hz, 1H), MH-698.

(단계 3-3): tert-부틸 2-((4R,6R)-6-(2-(2-(4-플루오로페닐)-4-((4-(하이드록시메틸)페닐)카바모일)-5-아이소프로필-3-페닐-1H-피롤-1-일)에틸)-2,2-디메틸-1,3-디옥산-4-일)아세테이트의 제조(Step 3-3): tert-butyl 2-((4R,6R)-6-(2-(2-(4-fluorophenyl)-4-((4-(hydroxymethyl)phenyl)carbamoyl) )-5-isopropyl-3-phenyl-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate

상기 단계 3-2에서 얻은 4-(1-(2-((4R,6R)-6-(2-(tert-부톡시)-2-옥소에틸)-2,2-디메틸-1,3-디옥산-4-일)에틸)-5-(4-플루오로페닐)-2-아이소프로필-4-페닐-1H-피롤-3-카복시아미도) 벤조산(1000 g)을 테트라하이드로퓨란(10 L)에 묽힌 후, 0℃로 냉각하였다. 40 ~ 45℃로 가열하여 보레인다이메틸설파이드(테트라하이드로퓨란 2 M 용액)(1.79 L)을적가한 뒤 하루 동안 교반하였다. 반응용액을 0℃로 냉각 후, 메탄올(2 L)을 천천히 적가하여 반응을 종결하였다. 반응용액을 감압 농축하여 아이소프로필 알코올: 증류수=4:1(v:v, 12 L) 용액에 묽힌 후,아세트산(0.087 L)을 적가하였다. 반응용액에 수산화칼슘(213 g)을넣어 1시간 동안 환류한 후, 고온에서 여과하였다. 여과된 고체는 아이소프로필 알코올:증류수=1:1(5 L)용액으로 한번 더 세척하였다. 여과물은 증류수(4 L)에 묽혀 3시간 동안 상온에서 교반하였고, 생성된 고체는 여과시켜 차갑게 식힌 아이소프로필 알코올:증류수=1:1(2 L)을 이용해 씻어냈다. 생성된 고체는 하루 동안 50℃에서 진공 건조하여 tert-부틸 2-((4R,6R)-6-(2-(2-(4-플루오로페닐)-4-((4-(하이드록시메틸)페닐)카바모일)-5-아이소프로필-3-페닐-1H-피롤-1-일)에틸)-2,2-디메틸-1,3-디옥산-4-일)아세테이트를 얻었다.4-(1-(2-((4R,6R)-6-(2-(tert-butoxy)-2-oxoethyl)-2,2-dimethyl-1,3- obtained in step 3-2 above Dioxan-4-yl)ethyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxyamido) benzoic acid (1000 g) in tetrahydrofuran (10 After diluted in L), it was cooled to 0°C. After heating to 40 ~ 45 ℃ borein dimethyl sulfide (tetrahydrofuran 2 M solution) (1.79 L) was added dropwise and stirred for a day. After cooling the reaction solution to 0 °C, methanol (2 L) was slowly added dropwise to terminate the reaction. The reaction solution was concentrated under reduced pressure, diluted with isopropyl alcohol: distilled water = 4:1 (v:v, 12 L) solution, and then acetic acid (0.087 L) was added dropwise. Calcium hydroxide (213 g) was added to the reaction solution and refluxed for 1 hour, followed by filtration at high temperature. The filtered solid was washed once more with isopropyl alcohol: distilled water = 1:1 (5 L) solution. The filtrate was diluted in distilled water (4 L) and stirred at room temperature for 3 hours, and the resulting solid was filtered and washed with cold isopropyl alcohol:distilled water = 1:1 (2 L). The resulting solid was vacuum-dried at 50° C. for one day to obtain tert-butyl 2-((4R,6R)-6-(2-(2-(4-fluorophenyl)-4-((4-(hydroxymethyl)). )Phenyl)carbamoyl)-5-isopropyl-3-phenyl-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate was obtained.

고체 884 g(수율 90%)884 g solid (90% yield)

1H NMR(500 MHz, DMSO-d6) 9.78(NH, br s, 1H), 7.46(d, J = 8.5 Hz, 2H), 7.27-7.24(m, 2H), 7.21-7.15(m, 4H), 7.09-7.05(m, 4H), 7.02-6.99(m, 1H), 5.05(OH, t, J = 5.5 Hz, 1H), 4.39(d, J = 5.5 Hz, 2H), 4.13-4.08(m, 1H), 3.95-3.89(m, 1H), 3.80-3.74(m, 2H), 3.21(sep, J = 7.0 Hz, 1H), 2.30(dd, J = 15.0 Hz, 5.0 Hz, 1H), 2.19-2.15(m, 1H), 1.63-1.50(m, 2H), 1.38(s, 9H), 1.36(d, J = 7.0 Hz, 6H), 1.35-1.30(m, 1H), 1.31(s, 3H), 1.16(s, 3H), 0.96-0.89(m, 1H). 1 H NMR (500 MHz, DMSO-d 6 ) 9.78 (NH, br s, 1H), 7.46 (d, J = 8.5 Hz, 2H), 7.27-7.24 (m, 2H), 7.21-7.15 (m, 4H) ), 7.09-7.05 (m, 4H), 7.02-6.99 (m, 1H), 5.05 (OH, t, J = 5.5 Hz, 1H), 4.39 (d, J = 5.5 Hz, 2H), 4.13-4.08 ( m, 1H), 3.95-3.89 (m, 1H), 3.80-3.74 (m, 2H), 3.21 (sep, J = 7.0 Hz, 1H), 2.30 (dd, J = 15.0 Hz, 5.0 Hz, 1H), 2.19-2.15 (m, 1H), 1.63-1.50 (m, 2H), 1.38 (s, 9H), 1.36 (d, J = 7.0 Hz, 6H), 1.35-1.30 (m, 1H), 1.31 (s, 3H), 1.16 (s, 3H), 0.96-0.89 (m, 1H).

(단계 3-4): tert-부틸(3R,5R)-7-(2-(4-플루오로페닐)-4-((4-(하이드록시메틸)페닐)카바모일)-5-이소프로필-3-페닐-1H-피롤-1-일)-3,5-디하이드록시헵타노네이트의 제조(Step 3-4): tert-butyl (3R,5R)-7-(2-(4-fluorophenyl)-4-((4-(hydroxymethyl)phenyl)carbamoyl)-5-isopropyl Preparation of -3-phenyl-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate

상기 단계 3-3에서 얻은 tert-부틸 2-((4R,6R)-6-(2-(2-(4-플루오로페닐)-4-((4-(하이드록시메틸)페닐)카바모일)-5-아이소프로필-3-페닐-1H-피롤-1-일)에틸)-2,2-디메틸-1,3-디옥산-4-일)아세테이트(605 g)을 테트라하이드로퓨란(3 L)과 메탄올(3 L)과 증류수(3 L)에 묽힌 뒤, 1 N 묽은 염산(0.442 L)을 적가하여, 45℃에서 2시간 동안 교반하였다. 반응용액에 탄산수소나트륨(48.3 g)을 추가하여 반응을 종결하고 상온으로 냉각하여 교반하였다. 용매의 부피가 1/2 정도 감소할 때까지 감압 농축하여, 10% 에틸아세테이트/헥산(6 L)을 추가하였다. 반응용액을 50℃에서 30분간 교반한 뒤, 상온으로 냉각하여 1시간 동안 추가로 교반하였다. 생성된 고체를 여과하여 증류수(0.6 L)로 세척하였고, 얻어진 고체를 헥산(1.2 L)에 묽혀 슬러리를 만들고, 40℃에서 2시간 동안 교반하여 다시 여과하였다. 생성된 고체를 하루 동안 50℃에서 진공 건조하여 tert-부틸(3R,5R)-7-(2-(4-플루오로페닐)-4-((4-(하이드록시메틸)페닐)카바모일)-5-이소프로필-3-페닐-1H-피롤-1-일)-3,5-디하이드록시헵타노네이트를 얻었다.Tert-butyl 2-((4R,6R)-6-(2-(2-(4-fluorophenyl)-4-((4-(hydroxymethyl)phenyl)carbamoyl obtained in step 3-3 above )-5-isopropyl-3-phenyl-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate (605 g) in tetrahydrofuran (3 L), methanol (3 L) and distilled water (3 L) were diluted, 1 N diluted hydrochloric acid (0.442 L) was added dropwise, followed by stirring at 45° C. for 2 hours. The reaction was terminated by adding sodium hydrogen carbonate (48.3 g) to the reaction solution, and the mixture was cooled to room temperature and stirred. It was concentrated under reduced pressure until the volume of the solvent was reduced by about 1/2, and 10% ethyl acetate/hexane (6 L) was added. The reaction solution was stirred at 50° C. for 30 minutes, cooled to room temperature, and further stirred for 1 hour. The resulting solid was filtered and washed with distilled water (0.6 L), and the obtained solid was diluted in hexane (1.2 L) to make a slurry, stirred at 40° C. for 2 hours, and filtered again. The resulting solid was vacuum-dried at 50° C. for one day to obtain tert-butyl (3R,5R)-7-(2-(4-fluorophenyl)-4-((4-(hydroxymethyl)phenyl)carbamoyl) -5-isopropyl-3-phenyl-1H-pyrrol-1-yl)-3,5-dihydroxyheptanonate was obtained.

고체 516.5 g(수율 90.6%)516.5 g solid (90.6% yield)

1H NMR(500 MHz, DMSO-d6) 9.76(NH, br s, 1H), 7.45(d, J = 8.5 Hz, 2H), 7.26-7.23(m, 2H), 7.20-7.15(m, 4H), 7.09-7.05(m, 4H), 7.01-6.98(m, 1H), 5.05(OH, t, J = 6.0 Hz, 1H), 4.68(d, J = 5.0 Hz, 1H), 4.62(d, J = 5.0 Hz, 1H), 4.39(d, J = 6.0 Hz, 2H), 3.96-3.90(m, 1H), 3.83-3.73(m, 2H), 3.54-3.48(m, 1H), 3.22(sep, J = 7.0 Hz, 1H), 2.26-2.17(m, 2H), 1.65-1.58(m, 1H), 1.56-1.48(m, 1H), 1.45-1.39(m, 1H), 1.39(s, 9H), 1.37(d, J = 7.0 Hz, 6H), 1.31-1.25(m, 1H). 1 H NMR (500 MHz, DMSO-d 6 ) 9.76 (NH, br s, 1H), 7.45 (d, J = 8.5 Hz, 2H), 7.26-7.23 (m, 2H), 7.20-7.15 (m, 4H) ), 7.09-7.05 (m, 4H), 7.01-6.98 (m, 1H), 5.05 (OH, t, J = 6.0 Hz, 1H), 4.68 (d, J = 5.0 Hz, 1H), 4.62 (d, J = 5.0 Hz, 1H), 4.39 (d, J = 6.0 Hz, 2H), 3.96-3.90 (m, 1H), 3.83-3.73 (m, 2H), 3.54-3.48 (m, 1H), 3.22 (sep) , J = 7.0 Hz, 1H), 2.26-2.17 (m, 2H), 1.65-1.58 (m, 1H), 1.56-1.48 (m, 1H), 1.45-1.39 (m, 1H), 1.39 (s, 9H) ), 1.37 (d, J = 7.0 Hz, 6H), 1.31-1.25 (m, 1H).

(단계 3-5): (3R,5R)-7-(2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-((4-히드록시 메틸 페닐 아미노)카보닐)-피롤-1-일)-3,5-디히드록시 헵탄산 헤미칼슘염의 제조(Step 3-5): (3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-((4-hydroxy methyl phenyl amino)carbonyl) Preparation of -pyrrol-1-yl)-3,5-dihydroxy heptanoic acid hemicalcium salt

상기 단계 3-4에서 얻은 tert-부틸(3R,5R)-7-(2-(4-플루오로페닐)-4-((4-(하이드록시메틸)페닐)카바모일)-5-이소프로필-3-페닐-1H-피롤-1-일)-3,5-디하이드록시헵타노네이트(1040 g)을 테트라하이드로퓨란(5 L)과 증류수(5 L)에 묽혀 교반하였다. 25 ~ 30℃에서 수산화나트륨(77.5 g)을 증류수(1.632 L)에 묽혀 반응용액에 적가한 뒤, 3시간 동안 교반하였다. 반응용액을 감압 농축한 후, 증류수(5 L)와 에틸아세테이트(5 L)을 넣어 10분간 교반하여 반응을 종결하였다. 유기층은 분리하고, 수성층은 에틸아세테이트(5 L)로 2회 세척하였다. 칼슘아세테이트(153 g)를 증류수(5 L)에 녹인 후, 수성층에 천천히 적가하였다. 반응용액은 하루 동안 상온에서 슬러리로 만든 후, 생성된 고체는 여과하여 소량의 증류수로 세척하였다. 생성된 고체는 에틸아세테이트(7 L)와 메탄올(0.7 L)과 증류수(7 L)에 묽힌 후, 부틸하이드록시아니솔(1.5 g)을 넣어 환류하였다. 반응용액을 상온으로 냉각하여 3시간 동안 교반하였다. 생성된 고체는 여과하여 소량의 물로 세척하여 하루 동안 50℃에서 진공 건조하여, 3R,5R)-7-(2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-((4-히드록시 메틸 페닐 아미노)카보닐)-피롤-1-일)-3,5-디히드록시 헵탄산 헤미칼슘염을 얻었다.Tert-butyl (3R,5R)-7-(2-(4-fluorophenyl)-4-((4-(hydroxymethyl)phenyl)carbamoyl)-5-isopropyl obtained in step 3-4 -3-Phenyl-1H-pyrrol-1-yl)-3,5-dihydroxyheptanonate (1040 g) was diluted in tetrahydrofuran (5 L) and distilled water (5 L) and stirred. Sodium hydroxide (77.5 g) was diluted in distilled water (1.632 L) at 25 to 30°C, added dropwise to the reaction solution, and stirred for 3 hours. After the reaction solution was concentrated under reduced pressure, distilled water (5 L) and ethyl acetate (5 L) were added and stirred for 10 minutes to terminate the reaction. The organic layer was separated, and the aqueous layer was washed twice with ethyl acetate (5 L). Calcium acetate (153 g) was dissolved in distilled water (5 L), and then slowly added dropwise to the aqueous layer. The reaction solution was made into a slurry at room temperature for one day, and the resulting solid was filtered and washed with a small amount of distilled water. The resulting solid was diluted with ethyl acetate (7 L), methanol (0.7 L) and distilled water (7 L), and then butylhydroxyanisole (1.5 g) was added to reflux. The reaction solution was cooled to room temperature and stirred for 3 hours. The resulting solid was filtered, washed with a small amount of water, and dried in vacuo at 50° C. for one day, 3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-( (4-hydroxymethylphenylamino)carbonyl)-pyrrol-1-yl)-3,5-dihydroxy heptanoic acid hemicalcium salt was obtained.

고체 852 g(수율 81.5%)852 g of solid (81.5% yield)

1H NMR(500 MHz, DMSO-d6) 9.82(NH, br s, 1H), 7.46(d, J = 8.5 Hz, 2H), 7.26-7.23(m, 2H), 7.21-7.14(m, 4H), 7.09-7.05(m, 4H), 7.01-6.98(m, 1H), 5.05(t, J = 5.5 Hz, 1H), 4.39(d, J = 5.5 Hz, 2H), 3.97-3.91(m, 1H), 3.79-3.73(m, 1H), 3.72-3.67(m, 1H), 3.54-3.50(m, 1H), 3.25-3.19(m, 1H), 2.02(dd, J = 15.0 Hz, 4.0 Hz, 1H), 1.87(dd, J = 15.0 Hz, 8.0 Hz, 1H), 1.63-1.56(m, 1H), 1.53-1.46(m, 1H), 1.40-1.35(m, 1H), 1.36(d, J = 7.0 Hz, 6H), 1.22-1.16(m, 1H), MH- 587(acid mass). 1 H NMR (500 MHz, DMSO-d 6 ) 9.82 (NH, br s, 1H), 7.46 (d, J = 8.5 Hz, 2H), 7.26-7.23 (m, 2H), 7.21-7.14 (m, 4H) ), 7.09-7.05 (m, 4H), 7.01-6.98 (m, 1H), 5.05 (t, J = 5.5 Hz, 1H), 4.39 (d, J = 5.5 Hz, 2H), 3.97-3.91 (m, 1H), 3.79-3.73 (m, 1H), 3.72-3.67 (m, 1H), 3.54-3.50 (m, 1H), 3.25-3.19 (m, 1H), 2.02 (dd, J = 15.0 Hz, 4.0 Hz , 1H), 1.87 (dd, J = 15.0 Hz, 8.0 Hz, 1H), 1.63-1.56 (m, 1H), 1.53-1.46 (m, 1H), 1.40-1.35 (m, 1H), 1.36 (d, J = 7.0 Hz, 6H), 1.22-1.16 (m, 1H), MH-587 (acid mass).

상기에서는 본 발명의 바람직한 실시예를 참조하여 설명하였지만, 해당 기술분야의 숙련된 당업자는 하기의 특허청구범위에 기재된 본 발명의 사상 및 영역으로부터 벗어나지 않는 범위 내에서 본 발명을 다양하게 수정 및 변경시킬 수 있음을 이해할 수 있을 것이다.Although the above has been described with reference to preferred embodiments of the present invention, those skilled in the art will be able to variously modify and change the present invention within the scope not departing from the spirit and scope of the present invention described in the following claims. You will understand that you can.

Claims (9)

(S1) 하기 화학식 A의 화합물과 하기 화학식 B의 화합물을 반응시켜, 하기 화학식 C의 화합물을 제조하는 단계;
(S2) 화학식 C의 화합물과 하기 화학식 D의 화합물을 반응시켜, 하기 화학식 E의 화합물을 제조하는 단계;
(S3) 화학식 E의 화합물로부터 하기 화학식 F의 화합물을 제조하는 단계;
(S4) 화학식 F의 화합물로부터 하기 화학식 G의 화합물을 제조하는 단계;
(S5) 화학식 G의 화합물로부터 하기 화학식 H의 화합물을 제조하는 단계; 및
(S6) 화학식 H의 화합물로부터 하기 화학식 1의 화합물을 제조하는 단계를 포함하는,
(3R,5R)-7-[2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-[(4-히드록시메틸페닐아미노)카보닐]-피롤-1-일]-3,5-디히드록시 헵탄산 헤미칼슘염의 제조방법;
[화학식 A]
Figure 112019071648864-pat00021

[화학식 B]
Figure 112019071648864-pat00022

[화학식 C]
Figure 112019071648864-pat00023

[화학식 D]
Figure 112019071648864-pat00024

[화학식 E]
Figure 112019071648864-pat00025

[화학식 F]
Figure 112019071648864-pat00026

[화학식 G]
Figure 112019071648864-pat00027

[화학식 H]
Figure 112019071648864-pat00028

[화학식 1]
Figure 112019071648864-pat00029

상기 화학식에서, R1 및 R2는 각각 독립적으로 C1-C6알킬을 나타내고,
X는 이탈기를 나타낸다.
(S1) preparing a compound of the following formula C by reacting a compound of the following formula A with a compound of the following formula B;
(S2) reacting a compound of formula C with a compound of formula D to prepare a compound of formula E;
(S3) preparing a compound of the following formula F from the compound of formula E;
(S4) preparing a compound of formula G from the compound of formula F;
(S5) preparing a compound of formula H from the compound of formula G; And
(S6) comprising the step of preparing a compound of formula 1 from a compound of formula H,
(3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxymethylphenylamino)carbonyl]-pyrrol-1-yl]- A method for producing hemicalcium salt of 3,5-dihydroxy heptanoic acid;
[Formula A]
Figure 112019071648864-pat00021

[Formula B]
Figure 112019071648864-pat00022

[Formula C]
Figure 112019071648864-pat00023

[Formula D]
Figure 112019071648864-pat00024

[Formula E]
Figure 112019071648864-pat00025

[Formula F]
Figure 112019071648864-pat00026

[Formula G]
Figure 112019071648864-pat00027

[Formula H]
Figure 112019071648864-pat00028

[Formula 1]
Figure 112019071648864-pat00029

In the above formula, R 1 and R 2 each independently represent C 1 -C 6 alkyl,
X represents a leaving group.
제1항에 있어서,
상기 화학식 B에서 X는 Cl, Br, I, 토실레이트(OTs), 트리플레이트(OTf) 또는 아세테이트(OAc)인,
(3R,5R)-7-[2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-[(4-히드록시메틸페닐아미노)카보닐]-피롤-1-일]-3,5-디히드록시 헵탄산 헤미칼슘염의 제조방법.
The method of claim 1,
In Formula B, X is Cl, Br, I, tosylate (OTs), triflate (OTf) or acetate (OAc),
(3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxymethylphenylamino)carbonyl]-pyrrol-1-yl]- Method for producing hemicalcium salt of 3,5-dihydroxy heptanoate.
제1항에 있어서,
하기 화학식 a-1의 화합물과 하기 화학식 a-2의 화합물을 반응시켜 화학식 A의 화합물을 제조하는 단계를 포함하는,
(3R,5R)-7-[2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-[(4-히드록시메틸페닐아미노)카보닐]-피롤-1-일]-3,5-디히드록시 헵탄산 헤미칼슘염의 제조방법;
[화학식 a-1]
Figure 112019071648864-pat00030
(이때, R1은 C1-C6알킬을 나타낸다)
[화학식 a-2]
Figure 112019071648864-pat00031
(이때, R3는 -O-(C1-C5알킬), Cl 또는 Br을 나타낸다)
The method of claim 1,
Comprising the step of preparing a compound of Formula A by reacting a compound of Formula a-1 with a compound of Formula a-2,
(3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxymethylphenylamino)carbonyl]-pyrrol-1-yl]- A method for preparing hemicalcium salt of 3,5-dihydroxy heptanoic acid;
[Formula a-1]
Figure 112019071648864-pat00030
(At this time, R 1 represents C 1 -C 6 alkyl)
[Formula a-2]
Figure 112019071648864-pat00031
(At this time, R 3 represents -O-(C 1 -C 5 alkyl), Cl or Br)
제1항에 있어서,
하기 화학식 b-1의 화합물과 하기 화학식 b-2의 화합물을 반응시켜 화학식 b-3의 화합물을 제조하는 단계; 및
화학식 b-3의 화합물을 할로겐화시켜 화학식 B를 제조하는 단계를 포함하는,
(3R,5R)-7-[2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-[(4-히드록시메틸페닐아미노)카보닐]-피롤-1-일]-3,5-디히드록시 헵탄산 헤미칼슘염의 제조방법;
[화학식 b-1]
Figure 112019071648864-pat00032

[화학식 b-2]
Figure 112019071648864-pat00033

[화학식 b-3]
Figure 112019071648864-pat00034

The method of claim 1,
Preparing a compound of formula b-3 by reacting a compound of formula b-1 with a compound of formula b-2; And
Comprising the step of preparing the formula B by halogenating the compound of formula b-3,
(3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxymethylphenylamino)carbonyl]-pyrrol-1-yl]- A method for preparing hemicalcium salt of 3,5-dihydroxy heptanoic acid;
[Formula b-1]
Figure 112019071648864-pat00032

[Formula b-2]
Figure 112019071648864-pat00033

[Formula b-3]
Figure 112019071648864-pat00034

하기 화학식 A의 화합물과 하기 화학식 B의 화합물을 반응시켜, 하기 화학식 C의 화합물을 제조하는 단계를 포함하는,
화학식 C로 나타내는 화합물의 제조방법;
[화학식 A]
Figure 112019071648864-pat00035

[화학식 B]
Figure 112019071648864-pat00036

[화학식 C]
Figure 112019071648864-pat00037

상기 화학식에서, R1 및 R2는 각각 독립적으로 C1-C6알킬을 나타내고,
X는 이탈기를 나타낸다.
Comprising the step of preparing a compound of the following formula C by reacting a compound of the following formula A with a compound of the following formula B,
A method for preparing a compound represented by formula C;
[Formula A]
Figure 112019071648864-pat00035

[Formula B]
Figure 112019071648864-pat00036

[Formula C]
Figure 112019071648864-pat00037

In the above formula, R 1 and R 2 each independently represent C 1 -C 6 alkyl,
X represents a leaving group.
제5항에 있어서,
하기 화학식 a-1의 화합물과 하기 화학식 a-2의 화합물을 반응시켜 화학식 A의 화합물을 제조하는 단계를 포함하는,
화학식 C로 나타내는 화합물의 제조방법;
[화학식 a-1]
Figure 112019071648864-pat00038
(이때, R1은 C1-C6알킬을 나타낸다)
[화학식 a-2]
Figure 112019071648864-pat00039
(이때, R3는 -O-(C1-C5알킬), Cl 또는 Br을 나타낸다)
The method of claim 5,
Comprising the step of preparing a compound of Formula A by reacting a compound of Formula a-1 with a compound of Formula a-2,
A method for preparing a compound represented by formula C;
[Formula a-1]
Figure 112019071648864-pat00038
(At this time, R 1 represents C 1 -C 6 alkyl)
[Formula a-2]
Figure 112019071648864-pat00039
(At this time, R 3 represents -O-(C 1 -C 5 alkyl), Cl or Br)
제5항에 있어서,
하기 화학식 b-1의 화합물과 하기 화학식 b-2의 화합물을 반응시켜 화학식 b-3의 화합물을 제조하는 단계; 및
화학식 b-3의 화합물을 할로겐화시켜 화학식 B를 제조하는 단계를 포함하는,
화학식 C로 나타내는 화합물의 제조방법;
[화학식 b-1]
Figure 112019071648864-pat00040

[화학식 b-2]
Figure 112019071648864-pat00041

[화학식 b-3]
Figure 112019071648864-pat00042

The method of claim 5,
Preparing a compound of formula b-3 by reacting a compound of formula b-1 with a compound of formula b-2; And
Comprising the step of preparing the formula B by halogenating the compound of formula b-3,
A method for preparing a compound represented by formula C;
[Formula b-1]
Figure 112019071648864-pat00040

[Formula b-2]
Figure 112019071648864-pat00041

[Formula b-3]
Figure 112019071648864-pat00042

제5항에 있어서,
화학식 A의 화합물과 화학식 B의 화합물의 반응은 염기 조건 또는 중성 조건 하에서 수행되는,
화학식 C로 나타내는 화합물의 제조방법.
The method of claim 5,
The reaction of the compound of formula A with the compound of formula B is carried out under basic conditions or neutral conditions,
Method for producing a compound represented by formula C.
제5항에 있어서,
화학식 A의 화합물과 화학식 B의 화합물의 반응은
톨루엔, 자일렌, 벤젠, 메틸렌클로라이드, 부탄올, 테트라하이드로퓨란, 에틸아세테이트, 프로판올, 사이클로헥사논, 디에틸에테르, 디옥산, 에탄올, 메탄올, 피리딘, 아세톤, 아세토니트릴, n,n-디메틸포름아미드, 디메틸술폭사이드 또는 이들의 수용액을 포함하는 용매 하에서,
탄산칼륨, 탄산리튬, 탄산나트륨, 탄산세슘, 수산화리튬, 수산화나트륨, 수산화칼륨, 1,8-디아자비사이클로(5.4.0)언덱-7-엔(DBU), N,N-디이소프로필에틸아민(DIPEA), 트리에탄올아민(TEA), 피리딘, 수소화나트륨 또는 포타슘 ter-부톡사이드(K[OC(CH3)3])의 염기 조건 하에서 수행되는,
화학식 C로 나타내는 화합물의 제조방법.
The method of claim 5,
The reaction of the compound of formula A and the compound of formula B is
Toluene, xylene, benzene, methylene chloride, butanol, tetrahydrofuran, ethyl acetate, propanol, cyclohexanone, diethyl ether, dioxane, ethanol, methanol, pyridine, acetone, acetonitrile, n,n-dimethylformamide , Under a solvent containing dimethyl sulfoxide or an aqueous solution thereof,
Potassium carbonate, lithium carbonate, sodium carbonate, cesium carbonate, lithium hydroxide, sodium hydroxide, potassium hydroxide, 1,8-diazabicyclo (5.4.0) undec-7-ene (DBU), N,N-diisopropylethylamine (DIPEA), triethanolamine (TEA), pyridine, sodium hydride or potassium ter-butoxide (K[OC(CH 3 ) 3 ]) carried out under basic conditions,
Method for producing a compound represented by formula C.
KR1020190084527A 2019-07-12 2019-07-12 Method of preparing(3r,5r)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-((4-hydroxymethylphenylamino)carbonyl)-pyrrol-1-yl)-3,5-dihydroxy-heptanoic acid hemi calcium salt, and method of preparing intermediates used therein KR102218320B1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
KR1020190084527A KR102218320B1 (en) 2019-07-12 2019-07-12 Method of preparing(3r,5r)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-((4-hydroxymethylphenylamino)carbonyl)-pyrrol-1-yl)-3,5-dihydroxy-heptanoic acid hemi calcium salt, and method of preparing intermediates used therein
CN202080049765.8A CN114096523A (en) 2019-07-12 2020-07-10 Process for preparing (3R,5R) -7- (2- (4-fluorophenyl) -5-isopropyl-3-phenyl-4- ((4-hydroxymethylphenylamino) carbonyl) -pyrrol-1-yl) -3, 5-dihydroxyheptanoic acid hemicalcium salt and process for preparing intermediates used therein
PCT/KR2020/009130 WO2021010681A2 (en) 2019-07-12 2020-07-10 Method for preparing (3r,5r)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-((4-hydroxymethylphenylamino)carbonyl)-pyrrole-1-yl)-3,5-dihydroxy heptanoic acid hemicalcium salt, and method for preparing intermediates used therein

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020190084527A KR102218320B1 (en) 2019-07-12 2019-07-12 Method of preparing(3r,5r)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-((4-hydroxymethylphenylamino)carbonyl)-pyrrol-1-yl)-3,5-dihydroxy-heptanoic acid hemi calcium salt, and method of preparing intermediates used therein

Publications (2)

Publication Number Publication Date
KR20210008263A KR20210008263A (en) 2021-01-21
KR102218320B1 true KR102218320B1 (en) 2021-02-23

Family

ID=74211124

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020190084527A KR102218320B1 (en) 2019-07-12 2019-07-12 Method of preparing(3r,5r)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-((4-hydroxymethylphenylamino)carbonyl)-pyrrol-1-yl)-3,5-dihydroxy-heptanoic acid hemi calcium salt, and method of preparing intermediates used therein

Country Status (3)

Country Link
KR (1) KR102218320B1 (en)
CN (1) CN114096523A (en)
WO (1) WO2021010681A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101329112B1 (en) * 2005-11-08 2013-11-14 랜박시 래보러터리스 리미티드 Process for (3r,5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
CN106397296A (en) * 2016-08-29 2017-02-15 江苏阿尔法药业有限公司 Preparation technology of atorvastatin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110117731A (en) * 2003-05-30 2011-10-27 랜박시 래보러터리스 리미티드 Substituted pyrrole derivatives and their use as hmg-co inhibitors
WO2005118536A1 (en) * 2004-05-31 2005-12-15 Ranbaxy Laboratories Limited Process for the preparation of atorvastatin
CN101304968A (en) * 2005-11-08 2008-11-12 兰贝克赛实验室有限公司 Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
WO2008010087A2 (en) * 2006-07-14 2008-01-24 Ranbaxy Laboratories Limited Polymorphic forms of an hmg-coa reductase inhibitor and uses thereof
CN102382006A (en) * 2011-11-11 2012-03-21 连云港宏业化工有限公司 Synthesis method of 2-[2-(4-fluorophenyl)-2-oxa-1-phenylethyl]-4-methyl-3-oxa-N-phenylpentanamide
KR102013157B1 (en) * 2015-03-31 2019-08-23 대원제약주식회사 Crystalline form and Method of preparing the same
KR102001835B1 (en) * 2018-08-24 2019-07-19 대원제약주식회사 Method of preparing (3r,5r)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-((4-hydroxymethylphenylamino)carbonyl)-pyrrol-1-yl)-3,5-dihydroxy-heptanoic acid hemi calcium salt, intermediates used therein, and method of preparing the intermediates

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101329112B1 (en) * 2005-11-08 2013-11-14 랜박시 래보러터리스 리미티드 Process for (3r,5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
CN106397296A (en) * 2016-08-29 2017-02-15 江苏阿尔法药业有限公司 Preparation technology of atorvastatin

Also Published As

Publication number Publication date
CN114096523A (en) 2022-02-25
WO2021010681A2 (en) 2021-01-21
WO2021010681A3 (en) 2021-03-11
KR20210008263A (en) 2021-01-21

Similar Documents

Publication Publication Date Title
EP1351963B1 (en) A process for the synthesis of atorvastatin form v and phenylboronates as intermediate compounds
JP6122118B2 (en) Process for preparing pyrazole carboxylic acid derivatives
US7812179B2 (en) Process for the preparation of atorvastatin and intermediates
AU2018366342A1 (en) Method for preparing Baricitinib
KR102218320B1 (en) Method of preparing(3r,5r)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-((4-hydroxymethylphenylamino)carbonyl)-pyrrol-1-yl)-3,5-dihydroxy-heptanoic acid hemi calcium salt, and method of preparing intermediates used therein
KR101063146B1 (en) Method for preparing pitavastatin intermediate and method for preparing pitavastatin hemicalcium salt
JP4783998B2 (en) Preparation of (3R, 5S) -7-substituted-3,5-dihydroxyhept-6-enoic acid
JP7545696B2 (en) Pyrrolinone compounds and synthesis methods thereof
KR102001835B1 (en) Method of preparing (3r,5r)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-((4-hydroxymethylphenylamino)carbonyl)-pyrrol-1-yl)-3,5-dihydroxy-heptanoic acid hemi calcium salt, intermediates used therein, and method of preparing the intermediates
JPH08503195A (en) Tartronic acids, their acetalic ethers and O-esters
JP5796836B2 (en) Process for producing intermediate of pitavastatin or a salt thereof
KR100424393B1 (en) Process for the preparation of oxiracetam
US5087732A (en) Glutaric acid derivatives and preparation thereof
US5332840A (en) Method for preparing a benzaldehyde intermediate
JP2010500351A (en) Method for producing lactam tachykinin receptor antagonist
EP0578849B1 (en) Process for the preparation of 1,3-dioxane-4,6-dione derivates
JP2021526142A (en) Process for preparing 2- (1- (tert-butoxycarbonyl) piperidine-4-yl) benzoic acid
US5260467A (en) Glutaric acid derivatives and preparation thereof
JPS5825664B2 (en) Production method of guanidinocaproic acid ester
JP2004526752A (en) Method for producing Δ1-pyrrolines
US5157138A (en) Glutaric acid derivatives and preparation thereof
HU213475B (en) Process for producing substituted alkene-acid and its derivatives and pharmaceutical compositions containing the same
SU952104A3 (en) Process for producing derivatives of interphenylene-9-thiaxo-12-azaprostanic acid
KR100412334B1 (en) Novel process for preparing 4-substituted-1H-pyrrole-3-carboxylic acid ester
JPS6340186B2 (en)

Legal Events

Date Code Title Description
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant